Drug launched in May halts metastatic breast cancer, say researchers in Madrid
Tuesday, June 4, 2019 @ 6:58 PM
A DRUG which keeps metastatic breast cancer in check and provides patients with nearly two-and-a-half years grace before resistance sets in has been developed in Spain, and is now on the market.
Until now, women with breast cancer with positive hormone receptors which had spread were given a hormonal treatment which would keep the disease controlled for an average of a year, after which
the tumour would become immune to it, normally with fatal results.
But 400 Spanish women with an HER-positive strain of breast cancer which had come back and spread have been taking Abemaciclib along with the standard hormonal treatment, via clinical trials, and are responding well, says the research team.
Sold under the brand name of Verzenios, the drug stops the cancer progressing for an average of 28.2 months, according to the Lilly Foundation who developed it with the help of the GEICAM Group of cancer researchers and Madrid's Gregorio Marañón hospital oncology department.
Read more at thinkSPAIN.com